Testicular Cancer Pipeline Insights, 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Testicular
Cancer – Pipeline Insights, 2017″ drug pipelines to their
offering.

Testicular Cancer – Pipeline Insights, 2017 provides in depth insights
on the pipeline drugs and their development activities around the
Testicular Cancer. This report covers the product profiles in various
stages of development including Discovery, Pre-clinical, IND, Phase I,
Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other
development activities including technology, licensing, collaborations,
acquisitions, fundings, patent and USFDA & EMA designations details.
This report also provides detailed information on the discontinued and
dormant drugs that have gone inactive over the years for Testicular
Cancer.

This report also assesses the Testicular Cancer therapeutics by
Monotherapy, Combination products, Molecule type and Route of
Administration.

Scope:

• The report provides competitive pipeline landscape of Testicular Cancer
• The report provides pipeline products under drug profile section which
  includes product description, MOA, licensors & collaborators,
  development partner and chemical information
• Coverage of the Testicular Cancer pipeline on the basis of target,
  MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics
  development for Testicular Cancer and also provide company profiling
• The report also gives the information of dormant and discontinued
  pipeline projects
• Pipeline products coverage based on various stages of development
  ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy
  products, stage of development and molecule type

Key Topics Covered:

1. Testicular Cancer Overview
2. Testicular Cancer Pipeline Therapeutics
3. Testicular Cancer Therapeutics under Development by Companies
4. Testicular Cancer Filed and Phase III Products
5. Testicular Cancer Phase II Products
6. Testicular Cancer Phase I and IND Filed Products
7. Testicular Cancer Discovery and Pre-Clinical Stage Products
8. Drug Candidate Profiles
9. Testicular Cancer – Therapeutics Assessment
10. Companies Involved in Therapeutics Development for Testicular Cancer
11. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/b4k5sw/testicular_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Oncology
Drugs